|
Aug-17-26 02:04PM
|
Argenx Stock Heads for Record After Blockbuster Drug Delivers Another Win
|
link
|
(Barrons.com)
|
|
Aug-17-26 11:51AM
|
Argenxs stock rises on Phase III autoimmune myositis victory
|
link
|
(Clinical Trials Arena)
|
|
Aug-17-26 10:53AM
|
argenx Phase 3 ALKIVIA Trial Meets Primary Endpoint in Autoimmune Myositis
|
link
|
(InvestorsHub)
|
|
Aug-17-26 09:47AM
|
Argenx's Vyvgart Scored Another Win - Why Shares Bolted Higher
|
link
|
(Investor's Business Daily)
|
|
Aug-17-26 06:00AM
|
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
|
link
|
(Business Wire)
|
|
Aug-17-26 03:38AM
|
European Indexes Start Week Mostly Higher, Boosted by Tech, Pharma Stocks
|
link
|
(The Wall Street Journal)
|
|
Aug-17-26 01:00AM
|
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
|
link
|
(GlobeNewswire)
|
|
Aug-07-26 01:06AM
|
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ...
|
link
|
(GuruFocus.com)
|
|
Aug-06-26 07:48AM
|
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
|
link
|
(GlobeNewswire)
|
|
Aug-03-26 04:01PM
|
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
|
link
|
(GlobeNewswire)
|
|
Jul-28-26 05:35AM
|
Argenx signs agreement to buy Forte Biosciences for $2.2bn
|
link
|
(Pharmaceutical Technology)
|
|
Jul-27-26 09:57PM
|
Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today?
|
link
|
(Stocktwits)
|
|
Jul-27-26 12:23PM
|
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
|
link
|
(Proactive)
|
|
Jul-27-26 07:46AM
|
Argenx to acquire Forte in $2.2B deal for differentiated immune drug
|
link
|
(BioPharma Dive)
|
|
Jul-27-26 07:12AM
|
FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker
|
link
|
(Stocktwits)
|
|
Jul-27-26 06:47AM
|
Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx
|
link
|
(InvestorsHub)
|
|
Jul-27-26 06:46AM
|
Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline
|
link
|
(InvestorsHub)
|
|
Jul-27-26 01:29AM
|
Argenx to Buy Forte Biosciences for $2.2 Billion
|
link
|
(The Wall Street Journal)
|
|
Jul-27-26 01:07AM
|
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
|
link
|
(Business Wire)
|
|
Jul-23-26 05:02PM
|
argenx SE (ARGNF) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Advances
|
link
|
(GuruFocus.com)
|
|
Jul-23-26 11:30AM
|
argenx VYVGART Sales Rise 60% as Pipeline Readouts Approach
|
link
|
(InvestorsHub)
|
|
Jul-23-26 01:00AM
|
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
|
link
|
(GlobeNewswire)
|
|
Jul-16-26 01:00AM
|
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
|
link
|
(GlobeNewswire)
|
|
Jul-06-26 04:06PM
|
Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks
|
link
|
(InvestorPlace)
|
|
Jul-06-26 01:12PM
|
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point
|
link
|
(Investor's Business Daily)
|
|
Jul-04-26 08:01AM
|
Robinhood, Dell Lead 5 Stocks Near Buy Points With AI Tailwinds
|
link
|
(Investor's Business Daily)
|
|
Jul-01-26 01:14PM
|
Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth
|
link
|
(Investor's Business Daily)
|
|
Jun-25-26 11:33AM
|
Bayer Surges After Winning Its Supreme Court Roundup Challenge
|
link
|
(Investor's Business Daily)
|
|
Jun-24-26 10:32AM
|
Can Argenx Retake Its Record High - And A Buy Point - On A New Vyvgart Strategy?
|
link
|
(Investor's Business Daily)
|
|
Jun-23-26 01:00AM
|
argenx to Host Autoimmune Myositis R&D Webinar
|
link
|
(GlobeNewswire)
|
|
Jun-03-26 01:00AM
|
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
|
link
|
(GlobeNewswire)
|
|
May-28-26 01:00AM
|
argenx to Host Myositis R&D Webinar on June 23, 2026
|
link
|
(GlobeNewswire)
|
|
May-27-26 01:00AM
|
argenx to Present at Upcoming Investor Conferences
|
link
|
(GlobeNewswire)
|
|
May-20-26 01:20PM
|
Can a New Arthritis Drug Make Immunovant the Next Biotech Star?
|
link
|
(Barrons.com)
|
|
May-20-26 11:38AM
|
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
|
link
|
(Barrons.com)
|
|
May-18-26 08:34AM
|
The Biology Came First.
|
link
|
(Business Wire)
|
|
May-11-26 06:00AM
|
Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial
|
link
|
(BioPharma Dive)
|
|
May-08-26 05:20PM
|
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
|
link
|
(GlobeNewswire)
|
|
May-08-26 06:07AM
|
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
|
link
|
(BioPharma Dive)
|
|
May-07-26 09:03AM
|
Argenx Obliterates Profit Expectations On 'Solid Print' For Its Immunology Powerhouse
|
link
|
(Investor's Business Daily)
|
|
May-07-26 08:45AM
|
Argenx (ARGX) tops earnings expectations despite slight revenue shortfall
|
link
|
(InvestorsHub)
|
|
May-07-26 01:00AM
|
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
|
link
|
(GlobeNewswire)
|
|
May-06-26 04:30PM
|
argenx to Present at BofA Securities 2026 Health Care Conference
|
link
|
(GlobeNewswire)
|
|
May-06-26 04:01PM
|
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
|
link
|
(GlobeNewswire)
|
|
May-06-26 09:15AM
|
argenx SE (XBRU:ARGX) Q1 2026: Everything You Need To Know Ahead Of Earnings
|
link
|
(GuruFocus.com)
|
|
Apr-30-26 01:00AM
|
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
|
link
|
(GlobeNewswire)
|
|
Apr-18-26 01:00AM
|
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
|
link
|
(GlobeNewswire)
|
|
Mar-20-26 04:01PM
|
argenx announces Annual General Meeting of Shareholders on May 6, 2026
|
link
|
(GlobeNewswire)
|
|
Mar-11-26 08:36AM
|
Deutsche Bank lifts Argenx to Buy as valuation no longer demanding
|
link
|
(Investing.com)
|
|
Mar-09-26 08:14PM
|
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached
|
link
|
(Insider Monkey)
|
|
Mar-08-26 06:24AM
|
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock
|
link
|
(Insider Monkey)
|
|
Mar-06-26 01:00AM
|
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
|
link
|
(GlobeNewswire)
|
|
Mar-05-26 11:40AM
|
KMDA vs. ARGX: Which Stock Is the Better Value Option?
|
link
|
(Zacks)
|
|
Mar-03-26 06:28AM
|
argenx CEO Karen Massey Reaffirms Vision 2030, Teases VYVGART Catalysts at TD Cowen Conference
|
link
|
(MarketBeat)
|
|
Mar-02-26 11:24PM
|
Analyst Report: argenx SE
|
link
|
(Morningstar Research)
|
|
Feb-26-26 06:51PM
|
Analyst Report: argenx SE
|
link
|
(Morningstar Research)
|
|
Feb-26-26 04:09PM
|
argenx SE (ARGNF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Advances
|
link
|
(GuruFocus.com)
|
|
Feb-26-26 10:59AM
|
argenex Q4 Earnings Call Highlights
|
link
|
(MarketBeat)
|
|
Feb-26-26 09:01AM
|
Argenx Touts Positive Phase 3 Eye Disease Study Results
|
link
|
(Benzinga)
|
|
Feb-26-26 01:00AM
|
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
|
link
|
(GlobeNewswire)
|
|
Feb-26-26 12:30AM
|
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
|
link
|
(GlobeNewswire)
|
|
Feb-25-26 08:17PM
|
Nurix Therapeutics Stock Sees RS Rating Jump To 82
|
link
|
(Investor's Business Daily)
|
|
Feb-25-26 07:15AM
|
What To Expect From argenx SE (XBRU:ARGX) Q4 2025 Earnings
|
link
|
(GuruFocus.com)
|
|
Feb-24-26 01:14PM
|
CRISPR Therapeutics Stock Sees RS Rating Rise To 73
|
link
|
(Investor's Business Daily)
|
|
Feb-24-26 01:02PM
|
Xenon Pharmaceuticals Stock Scores RS Rating Upgrade
|
link
|
(Investor's Business Daily)
|
|
Feb-24-26 07:33AM
|
Artisan Mid Cap Fund Maintains Its Confidence in Argenx's (ARGX) VYVGART
|
link
|
(Insider Monkey)
|
|
Feb-23-26 01:00AM
|
argenx to Present at TD Cowen 46th Annual Healthcare Conference
|
link
|
(GlobeNewswire)
|
|
Feb-19-26 01:00AM
|
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
|
link
|
(GlobeNewswire)
|
|
Feb-18-26 11:17AM
|
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
|
link
|
(Zacks)
|
|
Feb-13-26 10:27AM
|
Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans
|
link
|
(MarketBeat)
|
|
Feb-11-26 11:40AM
|
HRMY vs. ARGX: Which Stock Is the Better Value Option?
|
link
|
(Zacks)
|
|
Feb-06-26 08:33AM
|
Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4
|
link
|
(Insider Monkey)
|
|
Feb-03-26 08:58PM
|
Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth
|
link
|
(Insider Monkey)
|
|
Jan-31-26 09:36AM
|
Argenx SE - ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone
|
link
|
(Insider Monkey)
|
|
Jan-30-26 11:15AM
|
Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season
|
link
|
(Investor's Business Daily)
|
|
Jan-30-26 02:07AM
|
Argenx's (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments
|
link
|
(Insider Monkey)
|
|
Jan-29-26 03:03PM
|
Wells Fargo Analyst Sees Potential in Argenx SE's (ARGX) Vyvgart, Increases PT to $1,317
|
link
|
(Insider Monkey)
|
|
Jan-28-26 09:13AM
|
argenx SE (ARGX): A Bull Case Theory
|
link
|
(Insider Monkey)
|
|
Jan-28-26 01:59AM
|
Why Argenx SE (ARGX) Stock Advanced on Commercial Execution
|
link
|
(Insider Monkey)
|
|
Jan-26-26 07:26PM
|
Analyst Report: argenx SE
|
link
|
(Morningstar Research)
|
|
Jan-26-26 11:40AM
|
HRMY or ARGX: Which Is the Better Value Stock Right Now?
|
link
|
(Zacks)
|
|
Jan-13-26 01:00AM
|
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
|
link
|
(GlobeNewswire)
|
|
Jan-12-26 04:34PM
|
argenx Spotlights VYVGART Sales Surge, First Profitability Year and Expanding Pipeline at JPM Conference
|
link
|
(MarketBeat)
|
|
Jan-12-26 06:26AM
|
Argenx shares slip as Q4 results come in broadly in line
|
link
|
(Investing.com)
|
|
Jan-12-26 01:00AM
|
argenx Highlights 2026 Strategic Priorities
|
link
|
(GlobeNewswire)
|
|
Jan-09-26 06:38PM
|
Analyst Report: argenx SE
|
link
|
(Morningstar Research)
|
|
Jan-06-26 01:00AM
|
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
|
link
|
(GlobeNewswire)
|
|
Jan-05-26 01:00AM
|
argenx Announces Leadership Transition Marking Next Evolution of Growth
|
link
|
(GlobeNewswire)
|
|
Dec-30-25 11:40AM
|
KROS or ARGX: Which Is the Better Value Stock Right Now?
|
link
|
(Zacks)
|
|
Dec-18-25 08:50AM
|
Here Are Thursdays Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More
|
link
|
(24/7 Wall St.)
|
|
Dec-16-25 03:10PM
|
Meta Puts Instagram Reels On Amazon's Fire TV. How Video Fits Into Zuckerberg's AI Push.
|
link
|
(Investor's Business Daily)
|
|
Dec-16-25 08:04AM
|
Stock Market Today: Dow Dips Ahead Of Jobs Report; Palantir, Tesla Drop (Live Coverage)
|
link
|
(Investor's Business Daily)
|
|
Dec-15-25 04:34PM
|
Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse
|
link
|
(Investor's Business Daily)
|
|
Dec-15-25 01:00AM
|
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
|
link
|
(GlobeNewswire)
|
|
Dec-13-25 08:04AM
|
Eli Lilly Leads Five Stocks Near Buy Points In Divided Market
|
link
|
(Investor's Business Daily)
|
|
Dec-12-25 11:40AM
|
KROS vs. ARGX: Which Stock Is the Better Value Option?
|
link
|
(Zacks)
|
|
Dec-12-25 08:22AM
|
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
|
link
|
(Zacks)
|
|
Nov-28-25 10:07AM
|
Biotechs Are On A Big Run, And Two Stocks Have Buy Points
|
link
|
(Investor's Business Daily)
|
|
Nov-18-25 04:01PM
|
argenx Announces Results of Extraordinary General Meeting of Shareholders
|
link
|
(GlobeNewswire)
|
|
Nov-18-25 02:19PM
|
Vera Therapeutics Stock Earns RS Rating Upgrade
|
link
|
(Investor's Business Daily)
|
ED-Finanzas